@Peeteepoo et al,I used to enjoy doing stats and connecting the dots for predictive purposes,
but lately wrt PAA, I enjoy researching the biopharma market and connecting dots on potential buyouts and takeovers. More exciting and more intriguing to predict what the industry players are thinking … great lists & info, btw!
Neuroscience has become resurgent …With the increased acceptance in biomarker use and validation wrt autophagy:And with the intrusion of AI into the neurological and cancer spaces, with a focus on synergistic effects of drug combinations,
and big pharma eyeing off biotechs with potentially critical additions to their existing favoured products to guarantee efficacy outcomes, (and future pipelines)
and looking at average product development budgets of USD$2.3B—2.6B,
then that gets very interesting for near-term potential, and quite possibly ‘imminent’.(btw fyi UNSW has a functioning drug combo platform in collaboration with an asx AI-tech company - so watch that space if interested, google-y-o-r.)(not held…yet)Whilst the researchers are scrambling for new data on cryptic exons and peptides related to TDP-43 proteinopathy for ALS-FTD:And big pharma (Biogen, Eisai, J&J and Lilly) are madly unscrambling toxic Tau tangles and reducing/removing amyloid plaques for AD:And the FDA are proving to be pro-active:And yes, Biogen are looking:CR/SP shenanigans - too short-term mindset, too small-picture impatience for me.Everything that I’m seeing points towards highly significant outcomes for clinical trial validation, commercialisation, and the inevitability of a BP intervention wrt MPL and/or PAA.
I’m predicting a high probability of buyout/TO, and definitely not predicting when, what or how. I’m happy to wait for that particular MT announcement, -- days, weeks, months, — and watch the other developments occur, and they are, with outstanding regularity — I make it what, 8 significant announcements in 5 weeks — the management team and BOD are flying in hyperdrive mode.
cheers,
Ice
- Forums
- ASX - By Stock
- PAA
- PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-645
-
-
- There are more pages in this discussion • 178 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.5¢ |
Change
0.010(4.88%) |
Mkt cap ! $95.68M |
Open | High | Low | Value | Volume |
21.5¢ | 22.0¢ | 21.5¢ | $378.8K | 1.759M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13800 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.0¢ | 151261 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13800 | 0.215 |
6 | 304678 | 0.210 |
5 | 257125 | 0.205 |
15 | 540770 | 0.200 |
7 | 254593 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.220 | 151261 | 4 |
0.225 | 2084 | 1 |
0.230 | 54360 | 2 |
0.240 | 134752 | 2 |
0.245 | 270545 | 4 |
Last trade - 14.00pm 15/07/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online